CERS6 regulates the balance of ceramide species, impacting membrane integrity and signaling:
Overexpression of CERS6 shifts ceramide pools toward C16:0 at the expense of very long-chain (C22–C26) ceramides, altering sphingomyelin composition and downstream signaling .
Recombinant CERS6 studies have elucidated its role in multiple pathologies:
Recombinant CERS6 is pivotal in drug discovery and mechanistic studies:
Structural Insights: Cryo-EM structures (PDB: 8QZ6) guide inhibitor design targeting the His211 active site .
Biomarker Potential: Elevated CERS6 mRNA/protein levels correlate with poor chemotherapy response in T-ALL .
Gene Silencing: shRNA-mediated knockdown in diabetic models reduces renal fibrosis and ceramide accumulation .
Catalytic Mechanism: CERS6 transfers acyl chains via a covalent histidine intermediate, a target for small-molecule inhibitors .
Apoptosis Regulation: Modulates extrinsic apoptosis by binding CD95/Fas and disrupting DISC assembly in T-ALL .
Metabolic Reprogramming: In melanoma, CERS6 silencing upregulates HK, M2-PK, and LDHA activity, enhancing glycolysis .
Mitophagy Link: C16:0 ceramide accumulation in diabetic kidneys suppresses PINK1-dependent mitophagy, driving fibrosis .